Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 17

1.

Persistently active microbial molecules prolong innate immune tolerance in vivo.

Lu M, Varley AW, Munford RS.

PLoS Pathog. 2013 May;9(5):e1003339. doi: 10.1371/journal.ppat.1003339. Epub 2013 May 9.

2.

Hepatic uptake and deacylation of the LPS in bloodborne LPS-lipoprotein complexes.

Shao B, Munford RS, Kitchens R, Varley AW.

Innate Immun. 2012 Dec;18(6):825-33. doi: 10.1177/1753425912442431. Epub 2012 Mar 22.

3.

Prolonged hepatomegaly in mice that cannot inactivate bacterial endotoxin.

Shao B, Kitchens RL, Munford RS, Rogers TE, Rockey DC, Varley AW.

Hepatology. 2011 Sep 2;54(3):1051-62. doi: 10.1002/hep.24488. Epub 2011 Jul 27.

4.

ABCA1 promotes the efflux of bacterial LPS from macrophages and accelerates recovery from LPS-induced tolerance.

Thompson PA, Gauthier KC, Varley AW, Kitchens RL.

J Lipid Res. 2010 Sep;51(9):2672-85. doi: 10.1194/jlr.M007435. Epub 2010 May 15.

5.

Overproduction of acyloxyacyl hydrolase by macrophages and dendritic cells prevents prolonged reactions to bacterial lipopolysaccharide in vivo.

Ojogun N, Kuang TY, Shao B, Greaves DR, Munford RS, Varley AW.

J Infect Dis. 2009 Dec 1;200(11):1685-93. doi: 10.1086/646616.

6.

Host inactivation of bacterial lipopolysaccharide prevents prolonged tolerance following gram-negative bacterial infection.

Lu M, Varley AW, Ohta S, Hardwick J, Munford RS.

Cell Host Microbe. 2008 Sep 11;4(3):293-302. doi: 10.1016/j.chom.2008.06.009.

7.

A host lipase detoxifies bacterial lipopolysaccharides in the liver and spleen.

Shao B, Lu M, Katz SC, Varley AW, Hardwick J, Rogers TE, Ojogun N, Rockey DC, Dematteo RP, Munford RS.

J Biol Chem. 2007 May 4;282(18):13726-35. Epub 2007 Feb 24.

8.

Shield as signal: lipopolysaccharides and the evolution of immunity to gram-negative bacteria.

Munford RS, Varley AW.

PLoS Pathog. 2006 Jun;2(6):e67. Review. No abstract available.

9.

An inflammation-inducible adenoviral expression system for local treatment of the arthritic joint.

van de Loo FA, de Hooge AS, Smeets RL, Bakker AC, Bennink MB, Arntz OJ, Joosten LA, van Beuningen HM, van der Kraan PK, Varley AW, van den Berg WB.

Gene Ther. 2004 Apr;11(7):581-90.

PMID:
14973543
11.

Endogenous regulation of a therapeutic transgene restores homeostasis in arthritic joints.

Miagkov AV, Varley AW, Munford RS, Makarov SS.

J Clin Invest. 2002 May;109(9):1223-9.

12.

In vitro evaluation of an enhanced human serum amyloid A (SAA2) promoter-regulated soluble TNF receptor fusion protein for anti-inflammatory gene therapy.

Rygg M, Uhlar CM, Thorn C, Jensen LE, Gaughan DJ, Varley AW, Munford RS, Göke R, Chen Y, Whitehead AS.

Scand J Immunol. 2001 Jun;53(6):588-95.

13.

Gene therapy to prevent organophosphate intoxication.

Cowan J, Sinton CM, Varley AW, Wians FH, Haley RW, Munford RS.

Toxicol Appl Pharmacol. 2001 May 15;173(1):1-6.

PMID:
11350209
14.

Physiologically responsive gene therapy.

Varley AW, Munford RS.

Mol Med Today. 1998 Oct;4(10):445-51. Review.

PMID:
9793933
15.

A two-component expression system that responds to inflammatory stimuli in vivo.

Varley AW, Geiszler SM, Gaynor RB, Munford RS.

Nat Biotechnol. 1997 Oct;15(10):1002-6.

PMID:
9335054
16.

Inflammation-induced recombinant protein expression in vivo using promoters from acute-phase protein genes.

Varley AW, Coulthard MG, Meidell RS, Gerard RD, Munford RS.

Proc Natl Acad Sci U S A. 1995 Jun 6;92(12):5346-50.

Supplemental Content

Loading ...
Support Center